Company Description
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide.
The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.
It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA).
This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology.
The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services.
This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services.
The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies.
The company was incorporated in 2020 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 2020 |
| IPO Date | Nov 20, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 650 |
| CEO | William Martin |
Contact Details
Address: 10770 Wateridge Circle, Suite 200 San Diego, California 92121 United States | |
| Phone | 858 546 0004 |
| Website | maravai.com |
Stock Details
| Ticker Symbol | MRVI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $27.00 |
| CIK Code | 0001823239 |
| CUSIP Number | 56600D107 |
| ISIN Number | US56600D1072 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| William E. Martin III | Chief Executive Officer and Director |
| Kevin M. Herde CPA | Executive Vice President and Chief Financial Officer |
| Dr. Peter Michael Leddy Ph.D. | Executive Vice President and Chief Administrative Officer |
| Christine Dolan | Executive Vice President and GM of Cygnus Technologies |
| Andrew Burch | President of Nucleic Acid Production |
| Robert Andrew Eckert MBA | Chairman of the Board |
| Debra Hart | Senior Director of Investor Relations |
| Kurt Oreshack J.D. | Executive Vice President, General Counsel and Secretary |
| Rebecca Buzzeo | Executive Vice President and Chief Commercial Officer |
| Dr. Kate E. Broderick Ph.D. | Chief Innovation Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 18, 2024 | 8-K | Current Report |
| Dec 5, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 8, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 7, 2024 | 8-K | Current Report |
| Oct 29, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 22, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |